



Adult Immunization Status (AIS-E)

AIS-E Measure Description¹

The percentage of members 19 years of age and older who are up-to-date on recommended routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap), zoster and pneumococcal.

Why is AIS-E Important?¹

Vaccines are recommended for adults to prevent serious disease, hospitalization and death. Specifically, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommends adults ages 19 and older receive an annual influenza vaccine and booster doses every 10 years of either tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap) vaccine.

ACIP also recommends routine zoster vaccination for adults ages 50 and older and pneumococcal vaccination for adults ages 65 and older. Many adults are not fully vaccinated and improving adult vaccination is a national priority. For instance, the National Adult Immunization Plan outlines a set of actions needed to achieve optimal prevention of infectious disease and specifically recommends regular monitoring of recommended adult vaccines.

Best Practices

- ✓ Schedule appointments to coincide with required timeframes for immunization administration.
- ✓ During visits, talk about the importance of being immunized.
- ✓ Ensure the member's medical record includes immunization history from all sources.
- ✓ Reference the CDC Immunization Vaccine Schedule: <https://www.cdc.gov/vaccines/imz-schedules/index.html>

Numerator Compliance²

Rate 1: Immunization Status: Influenza (Age 19-65) - Members who received an influenza vaccine on or between July 1 of the year prior to the measurement period and June 30 of the measurement period, or members with anaphylaxis due to the influenza vaccine any time before or during the measurement period.

Rate 2: Immunization Status: Td/Tdap (Age 19-65) - Members who received at least one Td vaccine or one Tdap vaccine between 9 years prior to the start of the measurement period and the end of the measurement period, or members with a history of at least one of the following contraindications any time before or during the measurement period:

- Anaphylaxis due to the diphtheria, tetanus or pertussis vaccine.
- Encephalitis due to the diphtheria, tetanus or pertussis vaccine.

Rate 3: Immunization Status: Zoster (Age 50-65) - Members who received two doses of the herpes zoster recombinant vaccine at least 28 days apart, on October 20, 2017, through the end of the measurement period, or members with anaphylaxis due to the herpes zoster vaccine any time before or during the measurement period.

Rate 4: Immunization Status: Pneumococcal (Age 19-65) - Members who received at least one dose of an adult pneumococcal vaccine on or after their 19th birthday, before or during the measurement period, or members with anaphylaxis due to the pneumococcal vaccine any time before or during the measurement period.

Rate 5: Hepatitis B (Age 19-65) - Members who received at least three doses of the childhood hepatitis B vaccine with different dates of service on or before their 19th birthday.

- One of the three vaccinations can be a newborn hepatitis B vaccination during the 8-day period that begins on the date of birth and ends 7 days after the date of birth.

Members who received a hepatitis B vaccine series on or after their 19th birthday, before or during the measurement period, including either of the following:

- At least two doses of the recommended two-dose adult hepatitis B vaccine administered at least 28 days apart; or
- At least three doses of any other recommended adult hepatitis B vaccine administered on different days of service.

Members who had a hepatitis B surface antigen, hepatitis B surface antibody or total antibody to hepatitis B core antigen test, with a positive result any time before or during the measurement period. Any of the following meet criteria:

- A test with a result greater than 10 mIU/mL.
- A test with a finding of immunity.

Members with a history of hepatitis B illness any time before or during the measurement period. Do not include laboratory claims.

Members with anaphylaxis due to the hepatitis B vaccine any time before or during the measurement period.

Data Collection Method²

Administrative (Claims)



Trillium Percentages/NCQA National Averages¹

AIS-E	Measurement Year	Trillium	NCQA National Average
Rate 1: Influenza	2023	-	16.23
	2022	-	14.2
Rate 2: Td/Tdap	2023	-	40.01
	2022	-	36.7
Rate 3: Zoster	2023	-	11.25
	2022	-	7.8
Rate 4: Pneumococcal	2023	-	45.71
	2022	-	-
Rate 5: Hepatitis B	2023	-	-
	2022	-	-

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/>

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2